Letters by company

Pd-Rx Pharmaceutical

1 letter discussing PDRX. Everything written about it on this site is on its ticker page.

Cedar Creek Partners Cedar Creek Partners 2026 Second Quarter Results Cedar Creek Partners increased expert-market exposure while building positions in discounted microcaps and community banks. The fund argues that Exco Resources, Harbor Diversified and PHI Group are mispriced because trading restrictions, incomplete filings and flawed tender processes obscure underlying asset values, while Solitron’s defense backlog and strategic review provide a separate catalyst. Q2 ‘26 +5.4% ENDI $135MEXCE $1.1BHRBR $131MMIFF delisted